Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial

NCT07731828 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Phase

Phase 2

Started

2026-08-01

Last updated

2026-07-28

Condition(s) studied

Cervical Neoplasms

Investigational drug(s) / intervention(s)

Adebrelimab

Adebrelimab: Adebrelimab (1200 mg) is administered intravenously (IV) on Day 1 of each 21-day cycle (Q3W). Neoadjuvant Phase: Patients receive short-course radiotherapy (30 Gy in 6 fractions) concurrent with 2 cycles of Adebrelimab plus platinum-based chemotherapy (cisplatin or carboplatin). Adjuvant Phase: Following surgery, patients receive up to 3 additional cycles of Adebrelimab plus platinum. This is followed by maintenance therapy with Adebrelimab monotherapy (Q3W) for a total treatment duration of 1 year. High-risk patients (positive nodes/margins) may receive additional radiotherapy as clinically indicated.

Study summary

Brief Summary

A Phase II Single-Arm Clinical Trial of Short-Course Radiotherapy Combined with Adebrelimab and Platinum-Based Neoadjuvant Therapy for Locally Advanced Cervical Cancer

Background \& Objective:

This is a single-center, single-arm, Phase II clinical trial. The primary objective is to evaluate the pathological complete response (pCR) rate (defined as ypT0N0) following neoadjuvant therapy with short-course radiotherapy (SCRT) combined with Adebrelimab (an anti-PD-L1 monoclonal antibody) and single-agent platinum chemotherapy in patients with locally advanced cervical cancer (LACC).

Study Design:

Patients will receive SCRT followed by three cycles of neoadjuvant chemoimmunotherapy. After completion of neoadjuvant treatment, radical hysterectomy with pelvic lymphadenectomy (with or without para-aortic lymphadenectomy) will be performed.

Outcome Measures:

Primary Endpoint: Pathological Complete Response (pCR) rate assessed by a central pathologist.

Secondary Endpoints:

Objective Response Rate (ORR) and R0 resection rate (per RECIST 1.1).

Event-Free Survival (EFS) and 2-year EFS rate.

Incidence and severity of Treatment-Related Adverse Events (TRAEs, per NCI-CTCAE v5.0) and surgical complications (per Clavien-Dindo classification).

Feasibility and implementation rate of different adjuvant treatment strategies based on postoperative risk stratification.

Depth of response (major pathological response, MPR).

Inclusion Criteria:

Key eligibility criteria include:

Newly diagnosed, histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix.

Clinical stage IB3-IIA2 or IIIA (without parametrial invasion) per FIGO 2018 staging.

No evidence of extrapelvic lymph node metastasis or distant metastasis (confirmed by PET/CT or enhanced CT).

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Signed informed consent form prior to any study-specific procedure. Female aged 18 to 80 years (inclusive) at the time of signing informed consent. Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Clinical staging of IB3-IIA2, or IIIA without parametrial invasion (according to FIGO 2018 staging system); no pelvic lymph node metastasis confirmed by PET/CT, and no evidence of distant metastasis. No prior surgery, radiotherapy, or systemic anti-tumor therapy for locally advanced cervical cancer (LACC). At least one measurable lesion meeting RECIST 1.1 evaluation criteria. ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1. Adequate hematological, hepatic, and renal function within 14 days prior to enrollment (details to be confirmed in the full protocol). Exclusion Criteria: * Pregnant or lactating women, or women who intend to become pregnant during the study period and are unwilling to use effective contraception. Known hypersensitivity to adebrelimab, platinum-based drugs (cisplatin or carboplatin), or any component of the concomitant regimens. History of other malignant tumors within 5 years prior to enrollment, except for cured non-melanoma skin cancer or cervical intraepithelial neoplasia. Uncontrolled severe cardiovascular disease (e.g., NYHA Class III or IV heart failure, unstable angina pectoris, uncontrolled arrhythmias, or myocardial infarction within 6 months). Active autoimmune disease requiring systemic immunosuppressive or corticosteroid therapy. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or uncontrolled HIV infection. Uncontrolled severe infection requiring systemic antibiotic/antiviral therapy at enrollment. Prior participation in other clinical trials and received investigational drug within 4 weeks before enrollment. Concomitant disease or condition that, in the judgment of the Investigator, would place the subject at undue risk or interfere with the subject's participation in the trial or interpretation of trial results.

Primary outcome measure(s)

Pathological Complete Response (pCR) Rate — At the time of definitive surgery (approximately 6-8 weeks after completion of neoadjuvant therapy).

Trial sites (1)

Facility	City	Region	Status
The Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu	Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL Recruiting

SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma Starting soon

Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL Starting soon

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies Recruiting

Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07731828 on ClinicalTrials.gov ↗ ← All trials in China